TX-FLUENCE
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today the results from a series of multiyear global studies analyzing the effects of broad-spectrum white light on cannabis, Merlice tomatoes and bell peppers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210812005279/en/
The studies found that while spectrum sensitivity is cultivar-dependent, broad-spectrum lighting strategies—which include green light and other wavelengths largely absent in narrow-band spectra—improved crop yield, morphology and overall performance in selected cultivars when compared to narrow-band spectra with high ratios of red and far-red wavelengths.
“The results from our global studies show how effective broad-spectrum white light can be in improving crop performance for many cultivators around the world,” said Dr. David Hawley, principal scientist at Fluence. “Broad-spectrum strategies are about balance and flexibility in the spectrum itself as well as the overall cultivation approach. While there are certain scenarios in which narrow-band spectra, or pink light, may make sense from an energy efficiency or crop production perspective, we’ve found that many cultivars simply perform better under broad spectra across the KPIs cultivators care about most: yield, morphology and overall quality. Our latest research empowers us with new insights to assess each grower’s objectives, weigh those objectives against a facility’s unique financial, environmental and energy parameters, and then ultimately derive a tailored solution for each cultivator.”
Merlice tomatoes
A collaborative study with Wageningen University and Research (WUR)—led by researchers Leo Marcelis and Ep Heuvelink—evaluated differences in yield, morphology, development and quality for Merlice tomatoes grown with the VYPR top light series under four light spectra: PhysioSpecTM BROAD R4, PhysioSpec TM BROAD R6, PhysioSpecTM BROAD R8 and PhysioSpecTM DUAL R9B. BROAD R4, R6 and R8 all contain significant fractions of green light and other photosynthetically active wavelengths, while DUAL R9B is a narrow-band spectrum that contains almost no green light.
As researchers increased the ratio of red light in the overall spectrum, they recorded a linear decrease in yield. Compared to spectra with higher blue, red and far-red wavelengths, Merlice grown under broader spectrum lights yielded increases in fruit weight as high as 13 percent. Other tomato cultivars grown under broad-spectrum saw yield increases up to 14 percent.
Cannabis
Fluence conducted individual studies with WUR and Texas Original Compassionate Cultivation (TOCC), respectively. In the TOCC study, researchers studied Type I, Type II and Type III cannabis response to broad-spectrum R4, R6 and R8 under high PPFD. In each case, broad-spectrum R4 generated the most dry weight per plant. In Type I cannabis, PhysioSpecTM BROAD R4 generated 17 percent higher yields than the next highest yielding spectral solution, R6. Cannabis grown under broad-spectrum R4 also significantly improved morphology compared to plants cultivated under R6 or R8. Plants grown under broad-spectrum R4 were free of photobleaching in their upper buds, a development that typically occurs in plants grown with a higher fraction of red light.
In the WUR study, researchers found that in some cultivars, monoterpene and cannabinoid content, including THC, CBD and CBG, is significantly inversely proportional to the fraction of red light in the production spectrum. With these cultivars, R4 induced a 20 percent increase in cannabinoid compounds compared to spectra with red light ratios as high as 90 percent or more.
“The results of the TOCC and WUR intensity and spectrum studies are important for cannabis cultivators for two reasons,” Dr. Hawley said. “First, there is rarely a scenario in which they should grow cannabis under low PPFD. Our research continues to emphasize how much more beneficial it is to grow cannabis under higher PPFDs. Second, watch your red light ratio. There are a couple very specific cultivars and production situations that could benefit from narrow-band or high red/far-red and blue wavelengths. But it can also have detrimental effects on cannabinoid content, terpene ratios, yield and morphology, and would raise the risk of significant photobleaching of the canopy. That’s why we generally recommend growing cannabis with broad-spectrum under high PPFD.”
Bell pepper
Fluence also conducted studies with bell peppers at the Harrow Research and Development Centre in Ontario, Canada led by Dr. Xiuming Hao and Dr. Jason Lanoue. The collaborative research on bell pepper found that fruit quality significantly increased in Gina and Eurix cultivars under broad-spectrum lighting. Peppers grown under broader spectrum light increased average fruit size by up to 15 percent compared to others with higher blue and red wavelengths. An increase in the dry matter content—which is largely associated with fruit quality—also increased with increasing green light. It was also found that broad-spectrum lighting strategies proved the consistency of week-to-week production by leveling out a traditionally flush-prone crop cycle.
“Time and time again, our research with leading institutions around the world is proving that there is no universal spectral strategy for cultivators,” said David Cohen, CEO at Fluence. “For many crops and cultivars, however, it’s also showing the holistic benefits of broad-spectrum white light not just for the crop, but for a cultivator’s entire operation. That’s why we at Fluence have a multilayered approach to how we work with our cultivators. We continue to invest heavily in industry-leading research around the world. We provide cultivators with boots-on-the-ground expertise and experience in the form of our horticulture services team, and we identify the right light fixture and spectral strategy to help cultivators achieve their most important goals.”
Fluence’s ongoing global research initiatives include additional studies on strawberry, lettuce and cucumber cultivation. To learn more about Fluence and discover its latest research results, visit www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005279/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release
In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
